Arrowhead Stock Analysis

ARWR
 Stock
  

USD 31.09  1.46  4.93%   

Arrowhead Pharma price fall over the last few months could raise concerns from retail investors as the firm is trading at a share price of 31.09 on 521,411 in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in August. However, diversifying your holdings with Arrowhead Pharma or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.5. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Arrowhead Pharma partners.
Please continue to Trending Equities.
  
The Arrowhead Pharma stock analysis report makes it easy to digest most publicly released information about Arrowhead Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Arrowhead Stock analysis module also helps to analyze the Arrowhead Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Arrowhead Stock Analysis Notes

About 70.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 482.39. Arrowhead Pharma recorded a loss per share of 1.08. The entity last dividend was issued on the 29th of October 2010. The firm had 1:10 split on the 17th of November 2011. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 329 people. For more info on Arrowhead Pharma please contact Christopher Anzalone at 626 304 3400 or go to https://arrowheadpharma.com.

Arrowhead Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arrowhead Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arrowhead Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arrowhead Pharma generated a negative expected return over the last 90 days
Arrowhead Pharma has high historical volatility and very poor performance
Arrowhead Pharma is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 249.94 M. Net Loss for the year was (153.93 M) with profit before overhead, payroll, taxes, and interest of 138.29 M.
Arrowhead Pharma currently holds about 416.5 M in cash with (91.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93.
Roughly 70.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: Swelling losses havent held back gains for Arrowhead Pharmaceuticals shareholders since theyre up 646 percent over 5 years - Nasdaq

Arrowhead Pharma Upcoming and Recent Events

Earnings reports are used by Arrowhead Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arrowhead Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End28th of November 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Arrowhead Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Arrowhead Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Arrowhead Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Arrowhead Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
4th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
19th of July 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
10th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of May 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
25th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
18th of March 2022
Submission of Matters to a Vote of Security Holders
View
9th of February 2022
Unclassified Corporate Event
View

Arrowhead Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Arrowhead Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arrowhead Pharma backward and forwards among themselves. Arrowhead Pharma's institutional investor refers to the entity that pools money to purchase Arrowhead Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares12.3 M432.5 M
Vanguard Group IncCommon Shares10.1 M354.5 M
State Street CorpCommon Shares5.6 M196.6 M
Jpmorgan Chase CoCommon SharesM105.3 M
Alliancebernstein LpCommon Shares2.8 M98.5 M
Fmr LlcCommon Shares2.7 M96.6 M
Invesco LtdCommon Shares2.2 M77.5 M
Note, although Arrowhead Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arrowhead Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 3.33 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arrowhead Pharma's market, we take the total number of its shares issued and multiply it by Arrowhead Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Arrowhead Profitablity

Arrowhead Pharma's profitability indicators refer to fundamental financial ratios that showcase Arrowhead Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Arrowhead Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arrowhead Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arrowhead Pharma's profitability requires more research than a typical breakdown of Arrowhead Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (61.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (59.73) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.6.

Management Efficiency

The entity has return on total asset (ROA) of (13.41) % which means that it has lost $13.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (33.79) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharma management efficiency ratios could be used to measure how well arrowhead pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Arrowhead Pharma shows the mean deviation of 2.92, and Risk Adjusted Performance of (0.044824). Arrowhead Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and break down nineteen technical drivers for Arrowhead Pharma, which can be compared to its rivals. Please confirm Arrowhead Pharma standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Arrowhead Pharma is priced correctly, providing market reflects its regular price of 31.09 per share. Given that Arrowhead Pharma has jensen alpha of (0.036426), we suggest you to validate Arrowhead Pharma's prevailing market performance to make sure the company can sustain itself at a future point.

Arrowhead Pharma Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Moving Average is predictive technique used to analyze Arrowhead Pharma price data points by creating a series of averages of different subsets of Arrowhead Pharma entire price series.
.

Arrowhead Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arrowhead Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Christopher Anzalone over two months ago via Macroaxis 
Disposition of 551197 shares by Christopher Anzalone of Arrowhead Pharma subject to Rule 16b-3
Christopher Anzalone over two months ago via Macroaxis 
Exercise or conversion by Christopher Anzalone of 2501 shares of Arrowhead Pharma subject to Rule 16b-3
Oliver Tracie over two months ago via Macroaxis 
Arrowhead Pharma exotic insider transaction detected
Vakiener Victoria over three months ago via Macroaxis 
Arrowhead Pharma exotic insider transaction detected
Kenneth Myszkowski over six months ago via Macroaxis 
Sale by Kenneth Myszkowski of 3786 shares of Arrowhead Pharma
Christopher Anzalone over six months ago via Macroaxis 
Exercise or conversion by Christopher Anzalone of 146388 shares of Arrowhead Pharma subject to Rule 16b-3
De Backer Marianne over six months ago via Macroaxis 
Acquisition by De Backer Marianne of 6400 shares of Arrowhead Pharma subject to Rule 16b-3
Hamilton James C over six months ago via Macroaxis 
Sale by Hamilton James C of tradable shares of Arrowhead Pharma
Hamilton James C over six months ago via Macroaxis 
Acquisition by Hamilton James C of 55000 shares of Arrowhead Pharma subject to Rule 16b-3
Michael Perry over six months ago via Macroaxis 
Sale by Michael Perry of 2628 shares of Arrowhead Pharma
Mauro Ferrari over six months ago via Macroaxis 
Sale by Mauro Ferrari of 3400 shares of Arrowhead Pharma
Christopher Anzalone over six months ago via Macroaxis 
Exercise or conversion by Christopher Anzalone of 11806 shares of Arrowhead Pharma subject to Rule 16b-3

Arrowhead Pharma Predictive Daily Indicators

Arrowhead Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arrowhead Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Arrowhead Pharma Forecast Models

Arrowhead Pharma time-series forecasting models is one of many Arrowhead Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arrowhead Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Arrowhead Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arrowhead Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arrowhead shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Arrowhead Pharma. By using and applying Arrowhead Stock analysis, traders can create a robust methodology for identifying Arrowhead entry and exit points for their positions.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 329 people.

Current Arrowhead Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arrowhead analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arrowhead analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
89.5Buy8Odds
Arrowhead Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Arrowhead analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Arrowhead stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Arrowhead Pharma, talking to its executives and customers, or listening to Arrowhead conference calls.
Arrowhead Analyst Advice Details

Arrowhead Stock Analysis Indicators

Arrowhead Pharma stock analysis indicators help investors evaluate how Arrowhead Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arrowhead Pharma shares will generate the highest return on investment. By understating and applying Arrowhead Pharma stock analysis, traders can identify Arrowhead Pharma position entry and exit signals to maximize returns.
Quick Ratio3.25
Fifty Two Week Low26.81
Revenue Growth-29.40%
Average Daily Volume Last 10 Day919.69k
Shares Short Prior Month4.83M
Average Daily Volume In Three Month763.68k
Shares Percent Shares Out3.95%
Gross Margins100.00%
Forward Price Earnings-14.66
Short Percent Of Float4.61%
Float Shares103.03M
Fifty Two Week High84.83
Fifty Day Average41.13
Enterprise Value To Ebitda-19.82
Two Hundred Day Average44.99
Enterprise Value To Revenue11.84
Please continue to Trending Equities. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Arrowhead Pharma price analysis, check to measure Arrowhead Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharma is operating at the current time. Most of Arrowhead Pharma's value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arrowhead Pharma's price. Additionally, you may evaluate how the addition of Arrowhead Pharma to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Arrowhead Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharma. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arrowhead Pharma is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharma's value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharma's market value can be influenced by many factors that don't directly affect Arrowhead Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arrowhead Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.